FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Scholefield James H
2. Issuer Name and Ticker or Trading Symbol

Merck & Co., Inc. [ MRK ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP,Chief Info&Digital Officer
(Last)          (First)          (Middle)

MERCK & CO., INC., 2000 GALLOPING HILL ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

10/30/2019
(Street)

KENILWORTH, NJ 07033
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  10/30/2019    M    11436.0000  A $0.0000  11436.0000  D   
Common Stock  10/30/2019    F    4294.0000  D $85.1000  7142.0000  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit   (1) 10/30/2019    M        11436.0000   10/30/2019 (2) 10/30/2021  Common Stock  11436.0000  $85.1000  22872.0000  D   

Explanation of Responses:
(1)  Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
(2)  These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Scholefield James H
MERCK & CO., INC.
2000 GALLOPING HILL ROAD
KENILWORTH, NJ 07033


EVP,Chief Info&Digital Officer

Signatures
Faye C. Brown as Attorney-in-Fact for James H. Scholefield 11/1/2019
**Signature of Reporting Person Date


Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Merck Charts.

Merck & Co., Inc. News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Wednesday 1 May 2024 (12 hours ago) • Business Wire
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
Monday 29 April 2024 (2 days ago) • Business Wire
U.S. Stocks Climb Well Off Worst Levels But Close Mostly Lower
Friday 26 April 2024 (6 days ago) • IH Market News
Futures Pointing To Sharply Lower Open On Wall Street
Thursday 25 April 2024 (6 days ago) • IH Market News
Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings
Thursday 25 April 2024 (6 days ago) • IH Market News
Merck Announces First-Quarter 2024 Financial Results
Thursday 25 April 2024 (7 days ago) • Business Wire
Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-conta
Friday 19 April 2024 (2 weeks ago) • PR Newswire (Canada)
Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News
Wednesday 10 April 2024 (3 weeks ago) • IH Market News
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Thursday 4 April 2024 (4 weeks ago) • Business Wire
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Wednesday 3 April 2024 (4 weeks ago) • Business Wire
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Monday 1 April 2024 (1 month ago) • Business Wire
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
Thursday 28 March 2024 (1 month ago) • Business Wire